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Rationale and design of a trial improving outcome of type 2 Cardiovascular and cerebrovascular events are the
diabetics on hemodialysis. most important causes of death in diabetic patients on
Background. Non–insulin-dependent diabetes mellitus dial-
long-term dialysis therapy, accounting for 59% of overallysis patients have the highest cardiovascular mortality known
mortality in this group [1]. Approximately 12 to 19% ofin any group of patients. Mixed dyslipidemia with moderately
elevated low-density lipoprotein (LDL) cholesterol and high such deaths from cardiovascular causes are due to acute
levels of triglyceride-rich lipoproteins is common in this condi- myocardial infarction, but 60% of patients die within
tion. It is not known, however, whether patients with type 2
one year after acute myocardial infarction [2]. The caus-diabetes on dialysis with this form of dyslipidemia derive bene-
ative role for plasma low-density lipoprotein (LDL) infit from lipid-lowering therapy. Recently, drugs have become
available that potently lower triglyceride-rich, apoB-containing the development of coronary artery disease has been
lipoproteins and thus permit testing of this issue. This is the first well established in subjects without impairment of renaltrial to address specifically the issue of whether the excessive
function, but the exact role of dyslipidemia in vascularcardiovascular mortality of patients with type 2 diabetes on
dialysis can be lowered by statins. disease of diabetic patients with renal failure remains
Methods. The Die Deutsche Diabetes Dialyse Studie is a to be defined. In diabetes, the pathogenesis of vascular
prospective randomized placebo-controlled trial that tests the lesions is likely to be more complex, and clarification ofhypothesis that atorvastatin, a hydroxymethyl-glutaryl coen-
this point is therefore particularly important. Despitezyme A reductase inhibitor, decreases the rate of cardiovascu-
lar mortality and of nonfatal myocardial infarction in patients the burden of cardiac disease among patients on dialysis,
with type 2 diabetes who have been on hemodialysis treatment there are currently no published data or no concepts to
for no more than two years. The primary endpoint, cardiovascu-
improve long-term survival or quality of life. There arelar mortality, includes fatal myocardial infarction, sudden death,
several unanswered questions that are critical to knowingdeath during coronary intervention, death from heart failure,
and other coronary causes. Secondary endpoints comprise over- how to manage the plasma lipids of patients with or with-
all mortality, nonfatal cardiovascular events, fatal and nonfatal out diabetes and on long-term hemodialysis. Approxi-
cerebrovascular disease, and the mean percentage change in
mately 8% of hemodialysis patients were prescribed alipid profile from baseline. The trial enrolls 1200 men and women
lipid-lowering medication [3], despite the fact that evi-on hemodialysis for less than two years and with type 2 diabetes
at 150 centers throughout Germany. Inclusion criteria are age dence-based data on this particular treatment and pa-
of 18 to 80 years, low-density cholesterol of 80 to 190 mg/dl tient group are still lacking. To elucidate this question,(2.1 to 4.9 mmol/liter), and triglyceride levels of less than 1000
the Die Deutsche Diabetes Dialyse Studie was planned.mg/dl (11.4 mmol/liter). Patients are randomized to either inac-
tive (placebo) or active (atorvastatin, 20 mg/day) drug therapy.
The average duration of follow-up is more than 2.5 years. To
protect against a lower than expected rate of events, the trial MODERATELY ELEVATED PLASMA
will be continued until a predetermined fixed number of end- CHOLESTEROL LEVELS AND
points occurs in the entire cohort so that the predefined power HYPERTRIGLYCERIDEMIAof the trial will be guaranteed.
Conclusions. This trial was designed to demonstrate that The causative role for plasma LDL in the development
lipid lowering with atorvastatin will improve life expectancy of coronary artery disease in subjects without impairment
and quality of life in type 2 diabetics on hemodialysis. The
of kidney function is established. Lipid changes particu-resolution of this question is important because the genesis of
larly hypertriglyceridemia with low HDL are a recog-vascular lesions in this condition is multifactorial and the pre-
cise role of dyslipidemia has not been defined. nized hazard for cardiac survival in nonuremic patients
as well [5]. The role of dyslipidemia in diabetic patients
Key words: atorvastatin, cholesterol, diabetes, triglycerides. with renal failure is yet not well defined, and only few
data exist [6]. Studies in nonrenal populations have con- 1999 by the International Society of Nephrology
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Table 1. Eligibility criteria for the 4D-Studycentrated on the consequences and management of hy-
percholesterolemia resulting from elevated LDL levels. Inclusion criteria
Men and women with type 2 diabetes on hemodialysis for no moreIn contrast, the most important anomalies in uremia-
than 24 months.associated dyslipidemia are an increase in serum levels
Age 18–80 years.
of triglyceride, intermediate-density lipoprotein (IDL), Exclusion criteria
Serum LDL cholesterol ,80 or .190 mg/dl (,2.1 or .4.9 mmol/cholesterol-rich very low-density lipoprotein (VLDL),
liter)apolipoprotein B (apoB), and a decrease in serum levels
Fasting serum triglycerides .1,000 mg/dl (11.4 mmol/liter)of high-density lipoprotein (HDL) [7, 8]. In addition, Symptomatic hepatobiliary cholestatic disease, Abnormal liver
hypertriglyceridemic diabetic patients on hemodialysis function with SGOT or SGPT .33ULN.
Positive test for HbsAg, HIV or known hepatitis C.exhibit an enrichment of a highly atherogenic LDL sub-
Hematopoetic or systemic disease which is not related to end-stageclass (small dense LDL) [9]. From data published so far,
renal failure, exclusive uremia-associated anemia.
it is expected that patients exhibit an LDL cholesterol Non-amenorrhoeic women with child-bearing potential, who do not
use a medical relevant contraception.in the range of 140 to 160 mg/dl and fasting serum tri-
Cardiovascular event (such as CABG, PTCA) congestive heartglycerides of 250 to 300 mg/dl [6, 10].
failure or myocardial infarction during the last 3 months.
Previous unsuccessful kidney transplantation.
Hypertension resistant to therapy (systolic blood pressure continu-NONTRADITIONAL CARDIAC RISK FACTORS
ously .200 mg Hg or diastolic .110 mm Hg).
Hypo- or hyperthyroidism (TSH beyond normal values).Smoking, hypertension, hyperhomocysteinemia, and
Excessive ethanol intake defined as .3 drinks per day (1 drink 5high levels of fibrinogen and lipoprotein(a) originating
45 ml/45% ethanol or equivalent).from its genetically determined low molecular weight Prior sensitivity to HMG-CoA reductase inhibitors.
isoform were identified as independent risk factors in Significant gastrointestinal disease or surgery, which may interfere
with drug absorption, inclusive chronic pancreatitis withpatients receiving hemodialysis (abstract; Kates et al,
malabsorption.J Am Soc Nephrol 6:540, 1995) [11–15]. Furthermore,
Participation in another drug trial during the last 30 days prior to
patients with activated acute phase response and ele- randomization.
Unwilling to consent.vated serum concentrations of interleukin 6, tumor ne-
crosis factor-a, and C-reactive protein are at high risk for ULN is upper limit of normal.
cardiovascular complications [16, 17]. It is not currently
known whether benefit from lipid lowering with an
HMG-CoA reductase inhibitor will be potentiated or
PRERANDOMIZATION PERIOD (SCREENING)abrogated in the presence of several strong nontradi-
tional uremia-related cardiac risk factors. The medical staff of the dialysis unit screens patients
who are on regular hemodialysis treatment three times
per week. If the dialysis physician is not the patient’sSTUDY DESIGN
personal physician, the latter is made aware of the impli-The overall goal of this prospective, randomized, pla-
cations of the study. Patients, who give informed consentcebo-controlled trial is to determine whether lowering
will take part in a series of two qualifying visits. Docu-plasma cholesterol and triglycerides will decrease the
mented control of blood pressure is a prerequisite forprimary endpoint, that is, the sum of cardiovascular
entering the study. Specific dietary instructions are notdeath rate and nonfatal myocardial infarction in patients
given because patients on hemodialysis are already sub-with type 2 diabetes on maintenance hemodialysis for
ject to a restriction in food and fluid intake. The introduc-less than two years. Cardiovascular mortality comprises
tion of a lipid-lowering diet might further add to thefatal myocardial infarction, sudden death, death during
risk of malnutrition. All lipid-lowering agents must becoronary intervention, death from heart failure, and
other coronary causes. Secondary endpoints comprise stopped before the formal series of prerandomization
overall mortality, nonfatal cardiovascular events, fatal visits are started. Serum lipids are measured by the core
and nonfatal cerebrovascular events, total mortality, and laboratory in fasting blood. Patients who have their dial-
mean percentage change in lipid profile from baseline. ysis sessions in the afternoon are allowed to have a stan-
dardized carbohydrate-containing breakfast at least six
hours prior to blood sampling. Blood is drawn from thePOPULATION
dialysis arteriovenous fistula prior to the start of theInclusion criteria are men and women with type 2
hemodialysis session and prior to the administration ofdiabetes mellitus treated by maintenance hemodialysis
heparin. The average lipid levels of two qualifying visitsfor no more than two years in the age range 18 to 80
are used to determine patients eligibility. The patients’years. Exclusion criteria are serum LDL cholesterol of
lipid levels after randomization are not released to theless than 80 or more than 190 mg/dl (less than 2.1 or
patients, their physicians, or the investigators at the clini-more than 4.9 mmol/liter) and triglycerides of more than
cal centers. Clinical evaluation includes medical history,1000 mg/dl (11.4 mmol/liter). Additional criteria are
listed in Table 1. medication use, and physical examination.
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SERUM LIPID DETERMINATION The addition of other cholesterol-lowering drugs, such
as fibric acid derivatives or cholestyramine, is not permit-On the day of collection, serum samples are shipped
ted in order to not enhance the risk of side-effects fromby surface mail to the core laboratory. Aliquots of plasma
interactions.and serum are immediately frozen at –208C for subse-
quent collection and analysis in ancillary studies. Eighty-
five percent of samples arrive in the laboratory within CONTROL OF HYPERRESPONDERS
24 hours after collection and are analyzed in a blinded
If LDL cholesterol decreases to less than 50 mg/dlmanner within 24 hours. Serum total cholesterol and tri-
(1.3 mmol/liter), the dose of atorvastatin (or placebo) isglyceride concentrations are measured using enzymatic
decreased by 50%, and the response is reassessed withinmethods and reagents provided by Roche Diagnostics
the next two consecutive visits. In case of dosage reduction(CHOD-PAP and GPO-PAP, respectively; Montclair,
in one treatment arm, an identical dosage adjustment inNJ, USA). VLDL cholesterol, LDL cholesterol, and
a randomly selected patient of the corresponding treat-HDL cholesterol are determined by electrophoresis in
ment group is made in order to maintain study blindness.agarose gels and subsequent enzymatic staining for cho-
lesterol using the rapid electrophoresis system (REP,
HELENA Diagnostika GmbH, Hartheim, Germany).
MONITORING DURING THEUnlike the Friedewald formula, this method produces
TREATMENT PHASEaccurate measurements of LDL cholesterol in samples
The assessment of drug efficacy by blood sampling iswith elevated triglyceride concentrations [18].
obtained four weeks after randomization. Physical exami-
nations, adverse event recording, compliance check, and a
RANDOMIZATION
standard electrocardiogram are obtained in six-month in-
Randomization into the two treatment groups is strati- tervals and at the end of the study. Compliance evaluation
fied by the center so that a balance in therapy assignment by the physician or the study nurse, if thought necessary,
is guaranteed within each of the participating centers. can be done three times per week during the hemodialy-
Patients are randomized by a randomization code pre- sis sessions. Study end points and major noncardiovascu-
pared by the statistical coordinating center. lar events are recorded by the physician in charge.
PROTOCOL OF DRUG THERAPY
SAMPLE SIZE DETERMINATION AND
Atorvastatin (20 mg once daily) or matching placebo DURATION OF THE TRIAL
is administered. Patients are advised to take study drug
The study is planned to have a 90% power to detectat least two hours apart from phosphate binders, which
a 10% reduction in cardiovascular mortality at an alphaare usually ingested with meals. The expected effect of
value of 0.05 (two-sided, adjusted for two preplannedthis dose of atorvastatin is to reduce plasma LDL choles-
interim analysis and one final analysis). The log-rankterol by 44%, increase plasma HDL cholesterol by 12%,
test is used to compare the survival curves. To achieveand decrease plasma triglyceride by 33% [19]. Atorva-
this power, the protocol specifies that 1200 patients muststatin increases the expression of LDL receptors, thus
be entered and followed until a fixed number of endaccelerating the clearance of LDL from the circulation.
points have occurred (unless the trial is stopped earlierIt also decreases the rate of hepatic production of VLDL,
the precursors of IDL and LDL. It is expected that the on the basis of an interim analysis). All statistical tests
concentrations of the VLDL and IDL particles decrease. are done by intention-to-treat analysis. Exploratory eval-
Atorvastatin is well tolerated, and adverse reactions are uation is also done by “per-protocol” analysis. The antici-
few and are primarily mild. Clinical experience in pa- pated duration of follow-up will be more than four years.
tients with impaired renal function is limited [20]. Plasma The expected number of events will have occurred 2.5
protein binding of atorvastatin is 98 to 99%, and accumu- years after randomization. Recruitment is anticipated to
lation in uremic patients has not been shown. last 1.5 years. The trial is scheduled to end in March 2002.
CONTROL OF ELEVATED LOW-DENSITY ANALYSIS OF DATA
LIPOPROTEIN AND TRIGLYCERIDES
Outcome variablesThe core laboratory monitors the lipid levels of the
The primary outcome variable is the combined end-patients and adjusts the dosage. Some patients may dem-
point of nonfatal myocardial infarction and cardiovascu-onstrate LDL cholesterol levels during follow-up that
lar death (fatal myocardial infarction, sudden death, con-exceed the upper limit. If LDL cholesterol is more than
gestive heart failure, death attributable to a diagnostic190 mg/dl on two consecutive measurements, the patient
is offered to leave the protocol for active treatment. or therapeutic procedure involving the coronary arterial
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circulation, death from other coronary causes). The sec- at the various dialysis facilities and committee members
work without any reimbursement.ondary outcome variables are total mortality, nonfatal
cardiovascular events (initial or repeated coronary angio-
Reprint requests to Christoph Wanner, M.D., Department of Medi-
plasty or coronary artery bypass surgery), fatal and non- cine, Division of Nephrology, University Clinic, Josef-Schneider-Str. 2,
97080 Wu¨rzburg, Germany.fatal cerebrovascular events, and changes in serum lipids
E-mail: c.wanner@medizin.uni-wuerzburg.derelative to baseline.
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